The Supreme Cannabis Company, Inc. (TSX: FIRE, OTCQX: SPRFW) announced Tuesday it was delaying the launch of two products due to “minor” business setbacks caused by COVID-19.
The 7ACRES’ whole flower pre-rolls and PAX pods for the PAX Era vaporizer were slated to launch in the company’s third quarter, which ended March 31, 2020, but are now planned to launch in fiscal Q4.
These delays are caused by supplier and third-party testing disruptions, Supreme said in a press release.
During the coronavirus pandemic, Supreme said it will give its front-line employees a pay raise to thank them for their hard work.
To mitigate risk the company said it is encouraging employees to work remotely whenever possible and is spacing out employees the best it can. Shift sizes are being limited, time between shifts is being stretched, breaks are being staggered and everyone is being given masks and gloves.
The company also completed its first international cannabis shipment to Breath of Life International, Ltd., Israel’s largest producer of medical cannabis, Supreme said. This partnership will allow BOL Pharma to sell Truverra-branded medical cannabis to medical cannabis patients in Israel.
“With the support of BOL Pharma, we navigated both Canada and Israel’s complex regulatory landscapes to achieve compliance with regulatory authorities in both countries, including Health Canada, the Canadian Food Inspection Agency and Israel’s Ministry of Health and Ministry of Agriculture and Rural Development,” Supreme interim president and CEO Colin Moore said.
Supreme Cannabis establishes a new international revenue opportunity with its first export of medical cannabis from #Canada to #Israel under its international medical brand, @truverra. Read full release: https://t.co/IUUpGtvKAs #FollowTheFire #cannabis pic.twitter.com/gpgYVujmbe
— SUPREME. (@TheSupremeFIRE) April 2, 2020
Truverra cannabis is grown at Supreme’s 440,000 square foot facility in Kincardine, Ontario.
Israeli medical cannabis patients gained access to Truverra products March 30, and the company is already receiving positive feedback from patients, BOL Pharma CEO Tamir Gedo said.
Top image via The Supreme Cannabis Company